<code id='7034C9DE38'></code><style id='7034C9DE38'></style>
    • <acronym id='7034C9DE38'></acronym>
      <center id='7034C9DE38'><center id='7034C9DE38'><tfoot id='7034C9DE38'></tfoot></center><abbr id='7034C9DE38'><dir id='7034C9DE38'><tfoot id='7034C9DE38'></tfoot><noframes id='7034C9DE38'>

    • <optgroup id='7034C9DE38'><strike id='7034C9DE38'><sup id='7034C9DE38'></sup></strike><code id='7034C9DE38'></code></optgroup>
        1. <b id='7034C9DE38'><label id='7034C9DE38'><select id='7034C9DE38'><dt id='7034C9DE38'><span id='7034C9DE38'></span></dt></select></label></b><u id='7034C9DE38'></u>
          <i id='7034C9DE38'><strike id='7034C9DE38'><tt id='7034C9DE38'><pre id='7034C9DE38'></pre></tt></strike></i>

          fashion

          fashion

          author:hotspot    Page View:345
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more
          The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine
          The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          FDA poised to publish guidelines for clinical trial diversity

          AdobeTheFoodandDrugAdministrationispoisedtotelldrugandmedicaldevicemakershowtobetterincludepeopleofc